Summit lung cancer drug shows ‘striking’ benefit over Keytruda
Bio Pharma Dive
SEPTEMBER 8, 2024
Study results provide much-anticipated details to Summit’s claim earlier this year that its drug “decisively beat” Merck’s dominant immunotherapy.
Sun.Sep 08, 2024
340 
A Common Sleeping Pill May Reduce Buildup of Alzheimer’s Proteins, Study Finds
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 8, 2024
(Tero Vesalainen/iStock/Getty Images) There’s still so much we don’t know about Alzheimer’s disease, but the link between poor sleep and worsening disease is one that researchers are exploring with gusto.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology Excellence Awards 2024: Botanical Solution Inc.
Pharmaceutical Technology
SEPTEMBER 8, 2024
Botanical Solution Inc.
Phytopharmaceuticals to propel new avenues in research, leading to novel treatments: Dr Vidhu Aeri
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 8, 2024
The growing attention to phytopharmaceuticals in the Indian lifesciences landscape is an opportunity to develop potent botanical extracts, said Dr. Vidhu Aeri, Professor of Pharmacognosy & Phytochemistry and former Dean, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer
Fierce Pharma
SEPTEMBER 8, 2024
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer.
PEP-07 by Sentinel Oncology for Mantle Cell Lymphoma: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Mantle Cell Lymphoma.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
PEP-07 by Sentinel Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Relapsed Acute Myeloid Leukemia.
WCLC: MSD/Daiichi build case for phase 3 ADC for lung cancer
pharmaphorum
SEPTEMBER 8, 2024
Results of Ideate-Lung01 trial at WCLC back up MSD and Daiichi Sankyo's decision to move anti-B7-H3 ADC I-Dxd into phase 3 for small cell lung cancer
PEP-07 by Sentinel Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Refractory Acute Myeloid Leukemia.
Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes
JAMA Internal Medicine
SEPTEMBER 8, 2024
This multicenter retrospective cohort study examines the comparative effectiveness of lactated Ringer solution vs normal saline for fluid resuscitation in inpatients with sickle cell disease and vaso-occlusive episodes.
MNV-201 by Minovia Therapeutics for Pearson Syndrome: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Pearson Syndrome.
Nurse-Supported Self-Directed Cognitive Behavioral Therapy for Insomnia
JAMA Internal Medicine
SEPTEMBER 8, 2024
This randomized clinical trial examines the effectiveness of a nurse-supported, self-directed behavioral insomnia intervention for decreasing insomnia severity and improving sleep outcomes among veterans.
MNV-201 by Minovia Therapeutics for Subacute Necrotizing Encephalomyelopathy (Leigh Disease): Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Subacute Necrotizing Encephalomyelopathy (Leigh Disease).
Transforming Biopharma R&D at Scale: A Strategic Shift for the Future
Cloudbyz
SEPTEMBER 8, 2024
Biopharma remains one of the most important contributors to global health innovation. However, the changing scenario with rising R&D costs, increasingly complex regulatory landscapes, and intensified competition necessitates new strategies in biopharma companies to remain competitive and innovative. Insights into such change by McKinsey focus on digital tools and data-driven methods at the core while giving an equal role to changes at organizational structure.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BR-6002 by Boryung Pharmaceutical for Gastric Ulcers: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
BR-6002 by Boryung Pharmaceutical for Cardiovascular Disease: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.
BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Sonidegib phosphate by Sun Pharma Advanced Research for Non-Small Cell Lung Cancer: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
Sonidegib phosphate is under clinical development by Sun Pharma Advanced Research and currently in Phase I for Non-Small Cell Lung Cancer.
Safinamide mesylate by Zambon Co for Drug-Induced Dyskinesia: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Drug-Induced Dyskinesia.
SON-DP by Qurgen for Metastatic Ovarian Cancer: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Ovarian Cancer.
SON-DP by Qurgen for Metastatic Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Colorectal Cancer.
Interferon alfa-2b by Center for Genetic Engineering and Biotechnology for Genital Warts (Condylomata Acuminata): Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
Interferon alfa-2b is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Genital Warts (Condylomata Acuminata).
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
RD-129 by Nanjing IASO Biotherapeutics for Autoimmune Disorders: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
RD-129 is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase I for Autoimmune Disorders.
MAR-001 by Marea Therapeutics for Hypertriglyceridemia: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
MAR-001 is under clinical development by Marea Therapeutics and currently in Phase II for Hypertriglyceridemia.
JTE-162 by Japan Tobacco for Autoimmune Disorders: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Autoimmune Disorders.
JTE-162 by Japan Tobacco for Inflammation: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Inflammation.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Omalizumab biosimilar by Kashiv BioSciences for Chronic Urticaria Or Hives: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase III for Chronic Urticaria Or Hives.
Chenodiol by Mirum Pharmaceuticals for Cerebrotendinous Xanthomatosis: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 8, 2024
Chenodiol is under clinical development by Mirum Pharmaceuticals and currently in Pre-Registration for Cerebrotendinous Xanthomatosis.
Risk adjusted net present value: What is the current valuation of Fusion Pharmaceuticals’s FPI-1434?
Pharmaceutical Technology
SEPTEMBER 8, 2024
FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Cervical Cancer.
Risk adjusted net present value: What is the current valuation of Aslan Pharmaceuticals’s Eblasakimab?
Pharmaceutical Technology
SEPTEMBER 8, 2024
Eblasakimab is a monoclonal antibody commercialized by Aslan Pharmaceuticals, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content